Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
DRUG
3 trials
Sponsors
Takeda
Conditions
Colorectal Cancer
Colorectal Carcinoma
Phase 2
Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
Completed
NCT02337946
Takeda
Colorectal Carcinoma
Start: 2014-10-16
End: 2017-08-31
Updated: 2019-09-10
Phase 3
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Completed
NCT02394795
Takeda
Colorectal Cancer
Start: 2015-05-29
End: 2022-01-14
Updated: 2023-11-01
Unknown Phase
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
Active, not recruiting
NCT02394834
Takeda
Colorectal Cancer
Start: 2015-05-29
End: 2027-09-30
Updated: 2026-04-13
Related Papers
ctDNA dynamics and prognostic value during first-line treatment of metastatic colorectal cancer: Analysis from the phase 3 PARADIGM study.
Journal of Clinical Oncology
2026-05-27
Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis.
Journal of Clinical Oncology
2024-06-01
3 citations
Abstract 5844: Landscapes of acquired EGFR and VEGF resistance alterations in colorectal cancer: findings from the PARADIGM biomarker study
Cancer Research
2024-03-22
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer
Nature Medicine
2024-02-12
85 citations
First-line (1L) panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) with <i>HER2</i> amplification (<i>HER2</i>amp<i>+</i>), <i>RAS</i> wild type (WT) metastatic colorectal cancer (mCRC) according to tumor sidedness.
JCO Global Oncology
2023-08-01
Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and <i>RAS</i>/<i>BRAF</i> WT: A biomarker study of the phase III PARADIGM trial.
Journal of Clinical Oncology
2023-06-01
4 citations
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer
JAMA
2023-04-18
219 citations
Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.
Journal of Clinical Oncology
2023-01-24
33 citations
Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
Journal of Clinical Oncology
2022-06-08
66 citations
PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> (<i>KRAS/NRAS</i>) wild-type metastatic colorectal cancer.
Journal of Clinical Oncology
2021-01-20
8 citations
Abstract 1974: Clonal and subclonal mutational landscapes in circulating tumor DNA in metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study
Cancer Research
2020-08-15
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer
European Journal of Cancer
2019-08-20
23 citations
Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials
International Journal of Cancer
2019-01-08
31 citations
Development of oncogene panel for detecting predictive and prognostic factors of metastatic colorectal cancer
Annals of Oncology
2018-10-01
Abstract CT164: Circulating tumor DNA analysis for predictive and prognostic factors in patients with metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study
Cancer Research
2018-07-01
SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results
Annals of Oncology
2018-06-01
1 citations
SAPPHIRE: A randomized phase II study of mFOLFOX6 + panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6 + panitumumab in patients with colorectal cancer.
Journal of Clinical Oncology
2018-02-01
6 citations
mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
2017-03-01
5 citations
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer
Clinical Colorectal Cancer
2017-01-24
12 citations
PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with <i>RAS</i> (<i>KRAS/NRAS</i>) wild-type metastatic colorectal cancer.
Journal of Clinical Oncology
2016-05-20
3 citations
1 more papers not shown